The Execution and Management of a Complex Clinical Trial Elizabeth K. Walsh, RN ECTSS 2013 Conflicts of Interest Advisory Board for TAVR Administrators.

Slides:



Advertisements
Similar presentations
1 US Investigator Meeting DIAS-4, Chicago, July 2011 Good Clinical Practice (GCP) for Investigators and the Research Team.
Advertisements

2.2. Challenges and Limitations to Oversight Andres Soosaar, Estonia.
Overview of the Study Protocol
RARE Action Learning Day, November 2012 Park Nicollet Post Hospital Discharge Follow Up Calls Karen Loscheider, RN Kris Kopski, MD, PhD.
Tips to a Successful Monitoring Visit
Gerald Treiman, IRB Chair John Stillman, IRB Director Maureen Brinkman, IRB Administrator Ann Johnson, IRB Administrator.
Eastern cooperative oncology group ECOG ITrack Initiative Integrated Trial Development Process March 23, 2010 Donna Marinucci March 23, 2010 Donna Marinucci.
Nursing Research Opportunities in the USPHS CAPT. Victoria L. Anderson, RN, CRNP, MSN.
The IND and Clinical Trial Management Frances Richmond Director International Center for Clinical Trials.
David Cloutier Director, Research Center Management and Development Budgeting for Industry Sponsored Clinical Trials.
Monitoring and Auditing
Care Coordination Program for Heart Failure Susan Levine RN Director Clinical Resource Management Carolyn Timmons BSN,RN Lead Clinical Care Coordinator.
Sixth Annual Meeting March 12, :00am to 4:00pm Crowne Plaza National Airport Arlington, VA INTERMACS Annual Meeting March 2012.
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
Joint Commission Survey 2014 Elizabeth Dunn, RN BSN Relevance to INTERMACS.
1 Points to Consider of Protocol on Multinational Trial Masaaki Kuwahara, Ph.D. Takeda Chemical Industries, Ltd. The 4th Kitasato-Harvard symposium,
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
Using EDC-Rave to Conduct Clinical Trials at Genentech
Clinical Trial Infrastructure in Centres Lillian L. Siu Princess Margaret Hospital.
Internal Auditing in Research: The QA Process Research Education Series February 14, 2011 Sarah Dutkevitch, RN, OCN, Clinical Research Nurse Specialist.
Revenue Cycle Management Medical Technology Acquisition and Assessment Team Members: Joseph Dixon, Michael Morotti, Mari Pirie-St. Pierre, David Robbins.
Coordinator Training Session: March 11, 2012 Major Changes in Data EntryMyers 1 What is the same? What is reduced/removed? What is added/expanded? INTERMACS.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
Building Quality Assurance into Clinical Trials. Objectives for Today: Define Quality in Research Describe How to Initiate Corrective and Preventative.
Role of the Oncology Research Team Carmen B. Jacobs, RN, OCN, CCRP.
Monitoring, Audits, and Inspection Oh my! Rachel Sheppard Regulatory Director, OCRSS.
RESCUE 4701 Adverse Event Reporting October 16, 2010 Maria Oh, Director Protocol Development & Regulatory Compliance.
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
MODULE B: Case Report Forms Jane Fendl & Denise Thwing April 7, Version: Final 07-Apr-2010.
MARYLAND PATIENT SAFETY CENTER PERINATAL COLLABORATIVE AND LEARNING NETWORK Secretary’s Advisory Committee on Infant Mortality March 9, 2012 Raymond L.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
SIPLAS RO is a full service contract research organization CRO, offering nanotechnology, biopharmaceutical and medical device companies comprehensive.
The Role of the Research Office Joint Research & Enterprise Office (JREO) St George’s University of London and St George’s University Hospitals NHS Foundation.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
Yale Center for Clinical Investigation: Academic Home to the CTSA Secretary’s Advisory Committee on Human Research Protections (SACHRP) Presentation Tesheia.
ANN HENDRICH, RN, PHD, F.A.A.N. SENIOR VICE PRESIDENT, CLINICAL QUALITY & SAFETY CNO & EXECUTIVE DIRECTOR, PATIENT SAFETY ORGANIZATION SEPTEMBER 10, 2012.
Item 5d Texas RE 2011 Budget Assumptions April 19, Texas RE Preliminary Budget Assumptions Board of Directors and Advisory Committee April 19,
Integrating AMI Care Across a Healthcare Service System Safer Healthcare Now National WebEx October 19 th, 2009 Diane Shanks and Leila Lavorato.
Medical Device Consultants, Inc. Investing in a Clinical Program: Advice in a Challenging Economic Time MassMEDIC Medical Device Clinical Trials Update.
Using EDC-Rave to Conduct Clinical Trials at Genentech Susanne Prokscha Principal CDM PTM Process Analyst February 2012.
Development and Approval of Drugs and Devices EPI260 Lecture 6: Late Phase Clinical Trials April 28, 2011 Richard Chin, M.D.
Investigational Devices and Humanitarian Use Devices June 2007.
How to Start An Industry Sponsored Clinical Trial
C-1 Pegfilgrastim (Neulasta  ) Oncologic Drugs Advisory Committee Pediatric Subcommittee October 20, 2005 Amgen Inc.
Conducting Research at Lincoln IRB/HRPP Policies, Procedures & Good Clinical Practices B Kanna MD, MPH, FACP Associate Program Director of Internal Medicine.
Clinical Risk Management Department of Human Services l Aim - transparency, no-blame, improve hospital systems and patient outcomes l CRM Strategy - framework.
Circulatory System Devices Panel Questions for Discussion EMBOL·X Aortic Filter October 23, 2002.
Speaking Clinical Trials Marianne Kearney Director of Research Operations Neurological Clinical Research Institute Massachusetts General Hospital.
IRB BASICS BETTY WILSON, MS, CIP. CONCEPTS SUBMISSION APPROVAL RECRUITING WORKING WITH PRINCIPAL INVESTIGATOR (PI) /SPONSOR POLICIES DEVIATIONS RECORD.
The Regulation on Cell Therapy Products in Japan
Rare Diseases Clinical Research Network Data Management and Coordinating Center (RDCRN DMCC) Rosalie Holland LDN Investigator Meeting at WORLDSymposium.
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Clinical Trial Budgets
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Introduction Review and proper registration of Human Gene Transfer protocols is very complex. A protocol goes through rigorous review by multiple Committees.
The Role and Responsibilities of the Clinical Research Coordinator
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
Easing the Burden on the Clinical Site
Larry L. Wood Corporate Vice President Edwards Lifesciences
Annual Outcomes With Transcatheter Valve Therapy
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
The Ever-Expanding Patient Pool for TAVR:
Annual Outcomes With Transcatheter Valve Therapy
Elements of an Organized Regulatory Binder
Claire McKinley, PMP, CCRP
ARCADIA Coordinator Webinar
The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation 
Human Gene Therapy Institutional Review Procedures
Clinical Trial Budgets
Presentation transcript:

The Execution and Management of a Complex Clinical Trial Elizabeth K. Walsh, RN ECTSS 2013 Conflicts of Interest Advisory Board for TAVR Administrators Study Operations Steering Committee

January 2007 Planning Meeting for TAVR: The Heart Team November st TAVR Implant November 2011 FDA approval for Inoperable October 2012 FDA approval for High Risk October 2013 Completion of Intermediate Risk enrollment Future TAVR devices and Trials to start in the US Introduction Utilization of a Best Practice Model: Crucial for the execution of a Successful Landmark Trial A Single Site Timeline

Methods 2007 – Enrolled Partner – Present203 Enrolled Partner 2 (continuing) 2011 – Present275 Commercial Implants Over 2000 Patients Screened for TAVR

Data Capture Screening Baseline Index Procedure Discharge Follow up Study Exit Protocol Deviation Adverse Events Hospitalization Hemorrhage/Vascular Injury Neurological Myocardial Infarction Infection Thromboembolic Average Data Points per patient Screening to 5 Year Follow = 1840 CRF Pages = 92 (excluding AE Capture) Average Queries per Subject = 47 Tracking the Data Audit and Monitoring of the Data

Results Complex Patient Population 1840 Data Points collected per patient Multiple Adverse Events requiring 24 hour PI Review Resource Intense Continuing Education New Protocols and multiple Protocol Modifications Patient and Family Education Staff members throughout the hospital and outpatient Training New Research Staff –Regulatory –Safety –Meeting Trial Endpoints –Data Management –Consenting –Follow up –Inspection Readiness –Collaboration with clinical staff FDA Trials are Serious Business Follow the Rules Growth of Staff over time

Conclusion Since 2007 over 2000 patients screened for TAVR Heart Team Model: Strong Coordinator, Weekly Team Meetings TAVR Clinic: Key to Patient Flow Keeping up with the Volume Patient Protocols Evolved from Best Practices in Clinical Trial TAVR Model Excellent Example of Complex Clinical Trial TAVR Trial a template for transition to a commercial Program Challenging Patient Population Multiple Data Points Multiple Sub-studies Multiple protocol versions Large Volume of AEs High Profile Trial Cost Resources Intense Multiple Data locks/Deadlines Running a Complex Trial can be a heavy load What is a Complex Clinical Trial